Reply to price and value in cancer care

Jagpreet Chhatwal¹, Michael S Mathisen^{2

3}, Hagop M Kantarjian⁴

Affiliations

¹ Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Epocrates Medical Information, AthenaHealth, San Francisco, California.
³ Departments of Pharmacy and Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Free article

Comment

Jagpreet Chhatwal et al. Cancer. 2015.

Free article

. 2015 Nov 15;121(22):4098-9.

doi: 10.1002/cncr.29624. Epub 2015 Aug 6.

Jagpreet Chhatwal¹, Michael S Mathisen^{2

3}, Hagop M Kantarjian⁴

¹ Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Epocrates Medical Information, AthenaHealth, San Francisco, California.
³ Departments of Pharmacy and Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

No abstract available

Comment on

Are high drug prices for hematologic malignancies justified? A critical analysis.
Chhatwal J, Mathisen M, Kantarjian H. Chhatwal J, et al. Cancer. 2015 Oct 1;121(19):3372-9. doi: 10.1002/cncr.29512. Epub 2015 Jun 23. Cancer. 2015. PMID: 26102457
Price and value in cancer care.
Saret CJ, Cohen JT, Parsons SK, Neumann PJ. Saret CJ, et al. Cancer. 2015 Nov 15;121(22):4097-8. doi: 10.1002/cncr.29625. Epub 2015 Aug 6. Cancer. 2015. PMID: 26249850 No abstract available.